



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/522,373	03/10/2000	Lawrence A Loeb	16336-000730US	5107
20350 75	590 06/04/2003			
TOWNSEND AND TOWNSEND AND CREW, LLP			EXAMINER	
TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-383			LACOURCIERE, KAREN A	
			ART UNIT	PAPER NUMBER
			1635	19
			DATE MAILED: 06/04/2003	•

Please find below and/or attached an Office communication concerning this application or proceeding.

		FILE (OPY	
	Application No.	Applicant(s)	_
	09/522,373	LOEB ET AL.	
Office Action Summary	Examiner	Art Unit	_
	Karen A. Lacourciere	1635	
The MAILING DATE of this communication a	ppears on the cover sheet wit	h the correspondence address	
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perio - Failure to reply within the set or extended period for reply will, by statt - Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b). Status	I. 1.136(a). In no event, however, may a re eply within the statutory minimum of thirty d will apply and will expire SIX (6) MON ute, cause the application to become AB.	ply be timely filed (30) days will be considered timely. HS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).	
1) Responsive to communication(s) filed on 12	2 March 2003 .		
•	This action is non-final.		
3) Since this application is in condition for allow closed in accordance with the practice under			
Disposition of Claims			
4) Claim(s) 1-10,12-18,45-50 and 66 is/are per	nding in the application.		
4a) Of the above claim(s) is/are withdr	awn from consideration.		
5)⊠ Claim(s) <u>45-50</u> is/are allowed.			
6)⊠ Claim(s) <u>1,3,6-9,14 and 16</u> is/are rejected.			
7) Claim(s) <u>2, 4, 5, 10, 12, 13, 15, 17, 66</u> is/are	objected to.		
8) Claim(s) are subject to restriction and Application Papers	or election requirement.		
9)☐ The specification is objected to by the Examir	ner.		
10)☐ The drawing(s) filed on is/are: a)☐ acc	cepted or b) objected to by the	ne Examiner.	
Applicant may not request that any objection to			
11)☐ The proposed drawing correction filed on	is: a)□ approved b)□ d	sapproved by the Examiner.	
If approved, corrected drawings are required in	•	•	
12) ☐ The oath or declaration is objected to by the E	Examiner.		
Priority under 35 U.S.C. §§ 119 and 120			
13) Acknowledgment is made of a claim for forei	gn priority under 35 U.S.C. §	119(a)-(d) or (f).	
a) ☐ All b) ☐ Some * c) ☐ None of:		•	
 Certified copies of the priority docume 	nts have been received.		
2. Certified copies of the priority docume	nts have been received in A	oplication No	
Copies of the certified copies of the pr application from the International E See the attached detailed Office action for a lie	Bureau (PCT Rule 17.2(a)).		
14)⊠ Acknowledgment is made of a claim for dome	stic priority under 35 U.S.C.	§ 119(e) (to a provisional application).	
 a) ☐ The translation of the foreign language p 15) ☐ Acknowledgment is made of a claim for dome 			
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of I	Summary (PTO-413) Paper No(s) nformal Patent Application (PTO-152)	
S. Patent and Trademark Office			

Application/Control Number: 09/522,373

Art Unit: 1635

Page 2

DETAILED ACTION

Continued Prosecution Application

The request filed on March 12, 2003 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/522,373 is acceptable and a CPA has been established. An action on the CPA follows.

Double Patenting

The rejection of record of claims 1-10, 13-18, and 66 under 35 U.S.C. 101, set forth in the prior Office action mailed 10-30-02, as claiming the same invention as that of claims 1-18 of prior U.S. Patent No. 6,063,628 is withdrawn in response to the amendments filed December 18, 2002.

Claim Rejections - 35 USC § 112

The rejection of record of claims 45-50 under 35 U.S.C. 112, second paragraph, set forth in the prior Office action, mailed 10-30-2002, is withdrawn in response to Applicant's amendments filed 12-18-2002.

Claim Objections

Claim 18 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 18 depends from

Application/Control Number: 09/522,373

Art Unit: 1635

claim 1 and recites viruses which are not retroviruses and flaviviruses, as recited by amended claim 1 and, therefore, does not further limit claim 1.

Claim 7 is objected to because it contains a typing error. Specifically, claim 7 recites "1-â-D-ribofuranosylimidazole", however, the "â" should actually be "ß".

Correction is required.

Allowable Subject Matter

Claims 2, 4, 5, 10, 12, 13, 15, 17and 66 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claims 45-50 are allowed.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 3, 6- 9, 14 and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Larsen et al. (NAR, Vol 6, No. 4, April 1979).

Larsen et al. disclose administering an adenine analogue, Toyocamycin (TMC), to a murine cell line infected with the Friend virus, a murine retrovirus. They observe that the virions had a loss of infectivity during TMC treatment (see for example abstract)

Application/Control Number: 09/522,373

Art Unit: 1635

and further observe that TMC was incorporated into the RNA of the virion and a

Page 4

significant amount of virion sequences is lost (see for example page 1554) and,

therefore, would be considered mutated.

Therefore, Larsen et al. anticipates claims 1, 3, 6-9, 14 and 16.

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Karen A. Lacourciere whose telephone number is (703)

308-7523. The examiner can normally be reached on Monday-Thursday 8:30-6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, John L. LeGuyader can be reached on (703) 308-0447. The fax phone

numbers for the organization where this application or proceeding is assigned are (703)

308-4242 for regular communications and (703) 305-1935 for After Final

communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is (703) 308-

0196.

Karen A. Lacourciere June 2, 2003 KAREN LACOURCIERE

PATENT EXAMINER